Belite Bio Q3: FDA Skips Adcom for Tinlarebant NDA, PDUFA Set for February 12, 2027
BLTE sits 53% above its 52-week low of $102.
Summary
Belite Bio reported a Q3 2026 net loss of $30.3M and disclosed the FDA will not hold an advisory committee for the tinlarebant STGD1 NDA, with a PDUFA date of February 12, 2027. It also filed for approval in Singapore, the UK and Switzerland in October 2026.
Key Events · Earnings and Guidance · BLTE
-
FDA Waives Advisory Committee
The FDA informed Belite Bio it will not convene an advisory committee meeting to discuss the NDA for tinlarebant in STGD1; review is ongoing with a PDUFA target action date of February 12, 2027.
-
Additional Ex-US Filings Submitted
Marketing Authorization Applications for tinlarebant in STGD1 were submitted in October 2026 to Singapore's HSA, the UK's MHRA and Swissmedic through the Access Consortium, on top of the J-NDA filed in Japan in September 2026.
-
Losses Widen on Higher Spend
Q3 2026 R&D rose to $15.5M from $10.3M and SG&A to $21.4M from $12.7M, taking the quarterly net loss to $30.3M from $21.7M; nine-month net loss was $85.6M versus $52.3M.
-
Balance Sheet Funds Launch Prep
As of September 30, 2026 the company held $271.3M in cash and cash equivalents plus $502.7M in U.S. treasury bills and notes, versus $352.9M and $419.7M respectively at December 31, 2025.
Analysis · BLTE · Life Sciences
The headline item is procedural but meaningful: the FDA told Belite it will not convene an advisory committee to discuss the tinlarebant NDA in STGD1, removing a scheduled public risk event ahead of the February 12, 2027 PDUFA date. The company also disclosed that marketing applications went in to Singapore, the UK and Switzerland in October 2026 through the Access Consortium, widening the filing footprint beyond the US and Japan. Against that, spending is climbing fast: R&D rose to $15.5M from $10.3M and SG&A to $21.4M from $12.7M, pushing the quarterly net loss to $30.3M from $21.7M. With $271.3M of cash plus $502.7M in treasuries, funding is not the near-term issue — the binary is the FDA decision roughly three months out.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLTE was trading at $156.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $102.00 to $200.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.